Product Candidates
A Pipeline of Novel Cancer Therapies
AVEO Pharmaceuticals is committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. The company's lead product candidate tivozanib is an oral, once-daily, investigational tyrosine kinase inhibitor for which top-line results from a Phase 3 clinical study in advanced renal cell carcinoma (RCC) have been reported, and is being evaluated in other tumors.
Using its proprietary Human Response Platform™ (HRP), AVEO discovered the lead candidate from its promising antibody pipeline, ficlatuzumab, a novel HGF inhibitory antibody currently in Phase 2 development in patients with non-small cell lung cancer (NSCLC); and a preclinical antibody candidate, AV-203, that targets the ErbB3 (HER3) receptor and may have utility in a range of cancers.
*Aveo and Astellas Pharma Inc. have a worldwide agreement to co-develop and commercialize tivozanib outside of Asia
**Anti-ErbB3 program is strategically partnered with Biogen Idec